about
von Willebrand factor (VWF)-dependent human platelet activation: porcine VWF utilizes different transmembrane signaling pathways than does thrombin to activate platelets, but both require protein phosphatase functionInnate and adaptive immunity in immune thrombocytopeniaThe cellular immunology associated with autoimmune thrombocytopenic purpura: an update.IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity.Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG.Mechanism of action of IVIG in ITP.IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity.Mechanism of action of IVIG and anti-D in ITP.Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura.Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg.Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo.A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy.Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia.Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells.Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia.A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy.Mechanisms of platelet recovery in ITP associated with therapy.Adoptive-transfer effects of intravenous immunoglobulin in autoimmunity.Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP?The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia.CD44 antibodies and immune thrombocytopenia in the amelioration of murine inflammatory arthritis.Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway.Allogeneic platelet transfusions prevent murine T-cell-mediated immune thrombocytopenia.CD44 antibody-mediated amelioration of murine immune thrombocytopenia (ITP): mouse background determines the effect of FcγRIIb genetic disruption.A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects.CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia.Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity.CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia.Targeting FcγRs to treat antibody-dependent autoimmunity.Mechanistic properties of intravenous immunoglobulin in murine immune thrombocytopenia: support for FcγRIIB falls by the wayside.Applications of flow cytometry in the analysis of blood leukocytes.Intravenous immunoglobulin prevents murine antibody-mediated acute lung injury at the level of neutrophil reactive oxygen species (ROS) productionRhD Specific Antibodies Are Not Detectable in HLA-DRB1(*)1501 Mice Challenged with Human RhD Positive Erythrocytes.Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic miceAntigen-induced B lymphocyte activation involves the p21ras and ras.GAP signaling pathway.Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models?
P50
Q24309557-F7538A8E-40D4-4DC5-940F-420089E5F509Q26859642-823837EA-239C-4F43-8D08-712606353F79Q33329007-896AA131-B686-47AC-93D6-C6A263D62946Q33340127-D19BCABB-EFE6-49E4-A9FC-3C16CC9DA8CCQ33345890-11476DE2-56C5-47E6-AA52-A65BA75F5B23Q33346778-348AF0B1-F71F-4F8E-8B29-D41517407C86Q33347095-CEA1FC81-FA41-4A92-8357-517FB8F6DE68Q33347843-8116146B-8BEF-44BC-9991-E98F34100654Q33358049-C2680DD7-3089-4FB5-886F-F5E3E067F139Q33363202-9E9777C7-63B1-4CF5-9779-B7B9682FC103Q33364381-5CBE99AD-CF87-48B2-AC15-92FC6C10AD2DQ33368585-8F92B3FF-1FC9-40A2-8BD3-D45D634DC934Q33369379-B9A78774-4E5D-4F6A-8FA4-7188BACC36AAQ33370407-1A0A9AC8-F1F5-4A3F-A705-890FA3E6C87AQ33371273-4311D238-74BC-498E-9DBA-5D9DF003F690Q33372445-087F09A3-5FFF-439F-9215-A4C54EC69AE0Q33372543-48A6B93F-831B-4F23-8CAF-3832CE406852Q33379023-224862CC-59A4-47DA-ACC1-1F4D56DA1147Q33382517-0AD6430F-3DA3-426F-905D-AEFAC8E8219CQ33387489-60A88D95-4F55-4F08-9C90-A7E65BC12DD6Q33388366-0DBED292-259C-445F-9C00-E7D382CDC1C2Q33389188-8A890D55-547B-49DE-956A-F6D66EDC3F5FQ33392654-5E920D19-2BF1-4BD8-A17D-5C0E6972BF28Q33397659-C6AE9C8A-5357-446C-B150-3B555040BDD4Q33408519-11C38728-2D97-407E-BF17-BE4F53A870D3Q33409741-18ED7517-DC46-4C45-ADD6-55C5F3B61B4DQ33411639-44DC939A-83EB-4C99-BF35-9FC4E5D38F4FQ33419269-16FDE1D5-8744-4184-9806-83CE405E6D33Q33420988-A19051D0-BBBC-4E55-ADF8-6F2C0231CE01Q33423336-C47ACA59-35DA-4451-AFC4-02C8FD40D048Q33427026-87F90674-C5E5-498D-AE0D-8BEFD6DB5B73Q33427450-1451F999-BA11-4D6F-B5BC-1AC11EEE0F65Q33429843-CCAE9C66-2B94-4455-9C83-739DAC502FC9Q33433148-CE076662-4DD5-4183-8966-3B6BB259E111Q33571308-00D9894E-F9B7-462D-9D45-69620AF564CDQ34170859-A295B622-55FF-484B-BD25-B6F83547D65AQ34979941-D1B6CDE1-4263-42B8-AD9F-8392748825DEQ36361909-D96CC2B8-4CD8-422E-89CA-0BF83936AD7FQ36362541-7C61E28E-3110-4ED6-A571-9893910DA6FCQ37591806-D55BC03E-77C7-4930-88B7-D93A1FE367E9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alan H Lazarus
@ast
Alan H Lazarus
@en
Alan H Lazarus
@es
Alan H Lazarus
@nl
type
label
Alan H Lazarus
@ast
Alan H Lazarus
@en
Alan H Lazarus
@es
Alan H Lazarus
@nl
prefLabel
Alan H Lazarus
@ast
Alan H Lazarus
@en
Alan H Lazarus
@es
Alan H Lazarus
@nl
P106
P21
P31
P496
0000-0002-5051-6916